Accessed 22 Mar 2021
[11] Beyond glycemic control, certain GLP-1 receptor agonists have demonstrated significant benefits in weight management, cardiovascular risk reduction, and renal protection in patients with type 2 diabetes, though these benefits vary by specific agent
For patients with severe osteoporosis or very high fracture risk, NICE-approved anabolic therapies may be appropriate, including teriparatide, abaloparatide, or romosozumab
A research team led by Arun Sanyal, M.D., director of Virginia Commonwealth Universitys Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, and Philip Newsome, Ph.D., of Kings College London, has been involved in the clinical trials exploring the potential of semaglutide the GLP-1 receptor agonist used for Wegovy and Ozempic to treat people with this type of liver disease
Persistent tiredness could indicate that your body isn't adjusting as anticipated and may necessitate adjusting your dosage or a change in treatment plan